Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.|
|Storage buffer||PBS, pH 7.4|
|Contains||15mM sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1-10 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
This antibody recognizes an extracellular domain of TRAIL-R2 (DR5).
A suggested positive control for this product is Jurkat human peripheral blood leukemia T cells.
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DR5 contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSFS10/TEAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containg adaptor protein, is required for the apoptosis mediated by this protein.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
MA1-19416 was used in immunocytochemistry to investigate the role of upstream events in the extrinsic apoptotic pathway for cisplatin and a potent platinum (IV) complex-mediated enhancement of TRAIL-induced cancer cells killing
|Vondálová Blanárová O,Jelínková I,Szöor A,Skender B,Soucek K,Horváth V,Vaculová A,Andera L,Sova P,Szöllosi J,Hofmanová J,Vereb G,Kozubík A||Carcinogenesis (32:42)||2011|
apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; Fas-like protein; KILLER; KILLER/DR5; p53-regulated DNA damage-inducible cell death receptor(killer); TNF-related apoptosis-inducing ligand receptor 2; Trail receptor 2; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9
CD262; DR5; KILLER; KILLER/DR5; TNFRSF10B; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; UNQ160/PRO186; ZTNFR9